Zimmer Biomet Holdings (ZBH) has drawn investor attention after recent trading left the stock with mixed returns, including a loss over the past year despite modest year to date gains.

The recent 1 day share price return of 0.44% to US$91.40 and a modest 7 day gain sit against a 1 year total shareholder return decline of about 10%, indicating fading longer term momentum despite short term stability.

If Zimmer Biomet’s move toward robotics and data driven surgery has caught your eye, it could be a good moment to see how other healthcare AI names stack up using our screener for 37 healthcare AI stocks

With Zimmer Biomet trading at US$91.40, sitting at a 45% intrinsic discount and about 13% below analyst targets, the key question is simple: is there still an opportunity for investors here, or is future growth already fully reflected in the current price?

Most Popular Narrative: 11.3% Undervalued

Zimmer Biomet’s latest fair value narrative points to a value of $103 per share versus the current $91.40, framing the stock as modestly undervalued and heavily tied to execution in its core U.S. business and capital return plans.

The company's focused investment in digital health, robotics, and data-driven surgical solutions (including the ROSA and upcoming Monogram platforms) is increasing adoption of premium offerings, enabling margin expansion due to product mix and driving recurring revenues through connected care ecosystems, supporting higher net margins and earnings predictability.

Curious what kind of revenue growth, margin lift, and valuation multiple sit behind that fair value tag? The narrative leans on tighter execution, share repurchases, and premium robotics adoption. The full story connects these moving parts into one earnings path.

Result: Fair Value of $103 (UNDERVALUED)

However, that story can unravel if pricing pressure keeps revenue growth muted or if acquisitions like Paragon 28 and Monogram take longer to integrate cleanly.

Next Steps

With a mix of concerns and optimism running through this story, it helps to move quickly and test the numbers yourself by weighing the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If Zimmer Biomet has sparked your interest, do not stop there. Use a few focused stock lists to quickly surface other opportunities that match your investing style.

• Zero in on potential mispricings by scanning 61 high quality undervalued stocks that combine solid fundamentals with appealing entry points.
• Strengthen your income stream by reviewing 13 dividend fortresses aimed at delivering higher yields with staying power.
• Lower your overall portfolio stress by filtering for 70 resilient stocks with low risk scores that score well on resilience and financial stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.